In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

As of Thursday, December 11, Atossa Therapeutics, Inc.’s ATOS share price has surged by 9.41%, which has investors ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant  given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Adjuvant giredestrant significantly improved invasive DFS vs. standard-of-care endocrine therapy in patients with early-stage ...

History is lived forward, but is written in retrospect. “We know the end before we consider the beginning and we can never wholly recapture what it was to know the beginning only” (C. V. Wedgewood, ...

Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...